21 08, 2023 The metallodrug BOLD-100 is a potent inhibitor of SARS-CoV-2 replication and has broad-acting antiviral activity Neal Evan Caminsky2023-08-21T09:32:06-04:00August 21, 2023|Funded Research Results, Pillar 3|
27 06, 2023 Nanoplasmonic amplification in microfluidics enables accelerated colorimetric quantification of nucleic acid biomarkers from pathogens Neal Evan Caminsky2023-06-27T11:46:21-04:00June 27, 2023|Funded Research Results, Pillar 3|
17 03, 2023 SARS-CoV-2 Nsp2 contributes to inflammation by activating NF-kB Neal Evan Caminsky2023-03-17T09:37:00-04:00March 17, 2023|Funded Research Results, Pillar 3|
17 03, 2023 Natural evolution of SARS-CoV-2 variants in K18-ACE2 mice gives rise to more virulent virus and variant alleles associated with treatment resistance Neal Evan Caminsky2023-03-17T09:32:07-04:00March 17, 2023|Funded Research Results, Pillar 3|
27 01, 2023 Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation Neal Evan Caminsky2023-01-27T15:58:35-05:00January 27, 2023|Funded Research Results, Pillar 3|
7 11, 2022 Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants Neal Evan Caminsky2022-11-22T18:37:06-05:00November 7, 2022|Funded Research Results, Pillar 3|
2 11, 2022 Identifying markers of emerging SARS-CoV-2 variants in patients with secondary immunodeficiency Neal Evan Caminsky2022-11-15T09:12:37-05:00November 2, 2022|Funded Research Results, Pillar 3|
4 10, 2022 Cytokines and lipid mediators of inflammation in lungs of SARS-CoV-2 infected mice Neal Evan Caminsky2022-11-15T09:14:07-05:00October 4, 2022|Funded Research Results, Pillar 3|
30 09, 2022 A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS -CoV-2 infection Neal Evan Caminsky2022-11-15T09:14:05-05:00September 30, 2022|Funded Research Results, Pillar 3|
27 09, 2022 Human coronaviruses disassemble processing bodies Neal Evan Caminsky2022-11-15T09:14:02-05:00September 27, 2022|Funded Research Results, Pillar 3|
